Teleflex Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/9/2026)
| Balance Sheet | Total Assets | 6,947,240,000.00 | ROE | 44.98 % |
| Balance Sheet | Total Equity | 3,124,770,000.00 | ROA | -13.04 % |
| Cashflow | Capital Expenditures | -95,236,000.00 | P/FCF | 3,813.29 |
| Cashflow | Free Cash Flow | 1,446,000.00 | – | – |
| Cashflow | Operating Cash Flow | 96,682,000.00 | P/CF | 57.03 |
| Income | Earnings per Share (diluted) | -20.25 | Div. Yield | 1.10 % |
| Income | Net Income | -905,640,000.00 | P/E | -6.09 |
| Income | Shares Outstanding | 44,724,000.00 | P/B | 1.76 |
| Income | Total Revenue | 1,992,710,000.00 | P/S | 2.77 |
Ratios calculated on: 10/14/2026
Company Description
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.teleflex.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more